Johnson & Johnson (JNJ) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Johnson & Johnson (JNJ) Healthcare & Pipeline Overview

Johnson & Johnson is a diversified healthcare company built around Innovative Medicine and MedTech, serving therapeutic areas including immunology, oncology, neuroscience, cardiovascular and metabolism, while also supplying interventional, orthopaedic, surgical, and vision products. Its post-2023 portfolio emphasizes prescription medicines and medical technologies rather than consumer health brands.

What Is the Investment Thesis for JNJ?

Johnson & Johnson presents a diversified healthcare profile through two operating platforms: Innovative Medicine and MedTech. Innovative Medicine provides exposure to immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension, while MedTech adds interventional solutions, orthopaedics, surgery, and vision. The separation of Consumer Health into Kenvue in 2023 is a major portfolio event and leaves the company focused on prescription medicines and medical technologies. The supplied financial indicators show a $653B market capitalization, a P/E ratio of 29.2, a 21.5% profit margin, a 70.5% gross margin, a 2.06% dividend yield, and a beta of 0.23. These figures describe profitability, valuation, shareholder distributions, and measured market sensitivity, but the source does not provide revenue growth, earnings growth, free cash flow, product-level sales, or analyst estimates. Potential value drivers include continued innovation in the listed therapeutic areas, adoption of MedTech products, and the breadth of the company’s healthcare portfolio. Relevant risks include regulatory requirements, competitive pressure, product concentration, and uncertainty around future growth metrics not supplied here.

Based on FMP financials and quantitative analysis

JNJ Key Highlights

Market capitalization of $653B, indicating a large-scale healthcare company.

• Profit margin of 21.5%, providing a supplied measure of overall profitability.
• Gross margin of 70.5%, reflecting the reported relationship between revenue and cost of goods sold.
• P/E ratio of 29.2, giving a supplied valuation reference for the company’s earnings.
• Dividend yield of 2.06% and beta of 0.23, representing the provided shareholder-distribution and market-sensitivity indicators.

Who Are JNJ's Competitors?

JNJ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are JNJ's Key Strengths?

Diversified operating structure spanning Innovative Medicine and MedTech.

• Broad coverage of prescription therapeutic areas and medical-technology categories.
• Worldwide healthcare operations and 141,700 employees.
• Reported 70.5% gross margin and 21.5% profit margin.

What Are JNJ's Weaknesses?

The portfolio is concentrated in Innovative Medicine and MedTech after the 2023 Consumer Health separation.

• The supplied data does not provide revenue growth, segment revenue, product sales, or geographic revenue detail.
• The source does not quantify market share, pipeline value, or product-level performance.
• The company operates in fields requiring research, manufacturing, and regulatory execution.

What Could Drive JNJ Stock Higher?

JNJ catalyst: Continued research and development across Innovative Medicine therapeutic areas including oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension.

• Commercial activity across MedTech categories including interventional solutions, orthopaedics, surgery, and vision.
• Portfolio focus on Innovative Medicine and MedTech following the 2023 separation of Consumer Health into Kenvue Inc.
• Worldwide manufacture and sale of healthcare products across prescription and medical-technology categories.

What Are the Key Risks for JNJ?

Rich valuation — a P/E of 29.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $63.5M recently.
• Regulatory approval, compliance, and oversight requirements affecting prescription medicines and medical technologies.
• Competitive pressure from AbbVie Inc., UnitedHealth Group Incorporated, Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S.
• Product development and commercialization risk across complex diseases, surgical applications, interventional products, and vision products.
• Dependence on research, development, manufacture, and sale of healthcare products for business performance.
• Limited visibility in the supplied data regarding segment revenue, product concentration, geographic performance, pipeline milestones, and future growth.

What Are the Growth Opportunities for JNJ?

• Growth opportunity 1: Innovative Medicine can expand through research, development, manufacture, and sale of prescription products in the company’s identified therapeutic areas. These include immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The source does not provide market sizes, product pipelines, approval dates, or revenue forecasts, so the financial scale and timeline of this opportunity are Unknown. The relevant company-specific driver is the breadth of therapeutic coverage and the ability to serve complex diseases through a dedicated Innovative Medicine segment.
• Growth opportunity 2: Oncology and immunology provide two specifically identified areas for continued pharmaceutical activity. The company’s existing AI insight describes prescription products for various cancers and rheumatoid arthritis, while the business description identifies oncology and immunology as core focus areas. Market size, product-level growth, clinical milestones, and timing are Unknown in the supplied data. The opportunity therefore rests on continued development and commercialization of medicines addressing these diseases, supported by Johnson & Johnson’s research, manufacturing, and sales capabilities.
• Growth opportunity 3: MedTech expansion can come from the company’s interventional solutions portfolio, including electrophysiology and neurovascular care products. These offerings are used in clinical and procedural settings, creating a healthcare technology platform alongside the pharmaceutical business. The source does not quantify procedure volumes, market sizes, product adoption, geographic sales, or timelines, so those details are Unknown. A specific company-level growth avenue is the continued development and sale of technologies across multiple interventional categories rather than reliance on one device type.
• Growth opportunity 4: Orthopaedics and advanced surgery represent additional MedTech avenues. Johnson & Johnson’s described portfolio includes hips, knees, spine products, and advanced surgery solutions. These categories extend the company’s reach across surgical and implant-related applications and complement its interventional and vision businesses. The provided data does not include market-size estimates, procedure growth rates, product launches, competitive shares, or expected timelines. Accordingly, the opportunity can be identified by portfolio scope, while its magnitude and timing remain Unknown.
• Growth opportunity 5: Vision products, including disposable contact lenses sold under the ACUVUE brand, provide another distinct MedTech category. The presence of vision alongside interventional solutions, orthopaedics, and surgery contributes to diversification within the medical-technology platform. The source does not state ACUVUE revenue, market share, market size, geographic performance, or future product timetable, making those measures Unknown. The company-specific opportunity is continued activity in vision products while maintaining a portfolio spanning both clinical devices and consumer-facing vision applications.

What Are JNJ's Competitive Advantages?

• Diversification across Innovative Medicine and MedTech reduces reliance on a single healthcare category.
• Broad therapeutic coverage includes immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
• MedTech breadth spans interventional solutions, orthopaedics, surgery, and vision.
• Long operating history dating to the company’s 1887 founding provides an established healthcare platform, although the source does not quantify brand value or market share.
• Scale represented by 141,700 employees and worldwide operations, with the source not providing further scale comparisons.

What Does JNJ Do?

Johnson & Johnson is a healthcare holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. founded the company in 1887. The business has since evolved from its historical healthcare foundation into a diversified organization organized around two principal operating segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription products across immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The company’s stated therapeutic focus includes complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders. This segment depends on research and development, regulatory processes, manufacturing, and commercialization of prescription medicines for patients and healthcare providers. MedTech includes products used in interventional solutions, orthopaedics, surgery, and vision. Its described portfolio includes electrophysiology products, neurovascular care products, hips, knees, spine products, advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. These offerings place the company across multiple clinical and procedural settings rather than in a single therapeutic or device niche. Johnson & Johnson strategically separated its Consumer Health business into Kenvue Inc. in 2023. Former consumer health brands including TYLENOL, LISTERINE, and BAND-AID are now owned by Kenvue. This separation means the current Johnson & Johnson profile is centered on Innovative Medicine and MedTech, with a portfolio oriented toward prescription therapies and medical technologies. The company is headquartered in New Brunswick, New Jersey, United States, and has 141,700 employees. Its business description identifies worldwide operations, although the provided source data does not quantify revenue by geography, segment, product, or therapeutic area. Johnson & Johnson’s reported market capitalization is $594.63 billion. The company operates in the general drug manufacturers industry within the healthcare sector and competes with pharmaceutical, medical-device, and diversified healthcare companies. Its differentiation in the supplied data is the combination of broad therapeutic coverage, multiple MedTech categories, established healthcare brands and capabilities, and scale across research, manufacturing, and sales.

What Products and Services Does JNJ Offer?

• Researches and develops prescription medicines for complex diseases.
• Manufactures and sells products across the healthcare field worldwide.
• Operates an Innovative Medicine segment covering several therapeutic areas.
• Develops products for immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
• Provides MedTech products for interventional solutions, orthopaedics, surgery, and vision.
• Supplies electrophysiology and neurovascular care products.
• Offers orthopaedic products for hips, knees, and spine, along with advanced surgery solutions.
• Sells disposable contact lenses under the ACUVUE brand.

How Does JNJ Make Money?

• Generates healthcare revenue through the research, development, manufacture, and sale of prescription products in Innovative Medicine.
• Generates MedTech revenue through products used in interventional solutions, orthopaedics, surgery, and vision.
• Serves multiple therapeutic and procedural categories rather than relying on one healthcare product line.
• Operates through subsidiaries and worldwide healthcare activities, although the source does not provide segment or geographic revenue breakdowns.

What Industry Does JNJ Operate In?

Johnson & Johnson operates at the intersection of general pharmaceuticals and medical technology. Its Innovative Medicine segment addresses immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension, while MedTech covers interventional solutions, orthopaedics, surgery, and vision. The supplied peer set includes AbbVie Inc., UnitedHealth Group Incorporated, Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S, reflecting competition or comparison across large healthcare businesses. The source does not provide industry growth rates, total addressable market sizes, market shares, or peer financial comparisons. Within the supplied context, Johnson & Johnson’s positioning is defined by diversification across medicines and devices and by its worldwide healthcare operations.

Who Are JNJ's Key Customers?

• Patients receiving prescription treatments for complex diseases.
• Healthcare providers and institutions using medicines, medical devices, and surgical products.
• Clinical and procedural settings using interventional, electrophysiology, neurovascular, orthopaedic, and surgery products.
• Vision customers using disposable ACUVUE contact lenses.
• The source does not identify specific payer, government, hospital, or distributor customer concentrations.

Over the past six months, Johnson & Johnson insiders filed 30 SEC Form 4 transactions — 17 sales and 13 purchases. On net that is roughly 243K shares disposed (about $63.5M), a signal worth weighing alongside the fundamentals.

Wall Street analysts project Johnson & Johnson revenue of about $101.24B for fiscal 2026, with EPS near $11.59. The estimate reflects 5 contributing analysts.

Johnson & Johnson has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.4% above estimates on average.

Johnson & Johnson's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.49 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Johnson & Johnson stands at 26.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.5%, showing how much profit it generates from its asset base. JNJ trades at a trailing price-to-earnings ratio of 29.23, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.4%, the inverse of the P/E and a quick read on earnings relative to price.

Johnson & Johnson (JNJ) Valuation Context

Valued at $653B, JNJ is classified as a mega-cap stock. Relative to its peer group, JNJ's quantitative score of 89/100 is above the peer average of 68/100.

JNJ Revenue & Earnings Trend

In Q2 2026, JNJ generated $25.31B in top-line revenue, marking a sequential increase of 5.2%. The company recorded net income of $5.53B, with diluted EPS of $2.27. Quarter-over-quarter revenue has been mixed, typical for a mega-cap company operating in Healthcare. Across the four most recent quarters, JNJ averaged $2.16 in diluted EPS.

Company Profile

Johnson & Johnson operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in New Brunswick, US. The company is led by CEO Joaquin Duato. JNJ has traded publicly since 1962.

JNJ Financials

JNJ earnings history & estimates →

JNJ Latest News

JNJ Analyst Consensus

JNJ MoonshotScore

Latest Johnson & Johnson Analysis

JNJ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources